Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746043 | 1.00 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL16135518 | 1.00 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL7531470 | 0.84 | CACNA2D1 (0.36) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL28186788 | 0.83 | GABRP (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL12447855 | 0.80 | CACNA2D1 (0.45) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27679696 | 0.80 | SLC22A6 (0.45) | CACNA2D1CACNB3CACNA1CSLC22A6ALDH1A1 | |
| SCHEMBL4746539 | 0.78 | CA2 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL276530 | 0.77 | TSHR (0.36) | RNPEPSLC7A5ALDH1A1SMN1; SMN2 | |
| SCHEMBL4748897 | 0.77 | TSHR (0.36) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL20656600 | 0.77 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118772033-A | Synthesis method of pregabalin trimer | 中国科学院成都生物研究所 | 2024-10-15 | — | — | CN | claimed |
| CN-118772033-A | Synthesis method of pregabalin trimer | 中国科学院成都生物研究所 | 2024-10-15 | — | — | CN | disclosed |
| CN-118772033-A | Synthesis method of pregabalin trimer | 中国科学院成都生物研究所 | 2024-10-15 | — | — | CN | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2978748-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2978748-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016075082-A1 | STEREOSELECTIVE REDUCTIVE AMINATION OF ALPHA-CHIRAL ALDEHYDES USING OMEGA-TRANSAMINASES FOR THE SYNTHESIS OF PRECURSORS OF PREGABALIN AND BRIVARACETAM | SANDOZ AG (CH) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075082-A1 | STEREOSELECTIVE REDUCTIVE AMINATION OF ALPHA-CHIRAL ALDEHYDES USING OMEGA-TRANSAMINASES FOR THE SYNTHESIS OF PRECURSORS OF PREGABALIN AND BRIVARACETAM | SANDOZ AG (CH) | 2016-05-19 | — | — | WO | disclosed |
| EP-2978748-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | Pfizer Ireland Pharmaceuticals (IE) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2008127646-A2 | TRANSAMINASE-BASED PROCESSES FOR PREPARATION OF PREGABALIN | DSM IP ASSETS B.V. (NL) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | GABRE, GABRG1, GABRG2 | CACNA2D1 328/4885CACNB3 325/4885CACNA1C 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.